

The King's Centre for Integrative Chinese Medicine

INTEGRATING WISDOM,
CATALYSING INNOVATION



KING'S
College
LONDON

 KING'S HEALTH PARTNERS

King's CICM:

- A research-focused, interdisciplinary initiative within King's Health Partners (KHP), dedicated to addressing major challenges faced by the NHS through innovative integration of traditional Chinese medicine (TCM) with conventional medicine.

Approach:

- Breaking down barriers, fostering dialogue, and building collaborative partnerships.
- Harmonising two enduring medical philosophies.
- Integrating expertise and resources from TCM, conventional medicine, and cutting-edge science and technology.

Why King's CICM? *The NHS's current challenges necessitate the integration of function- and anatomy-oriented reasoning, as well as holistic and reductionist thinking.*


• The NHS at Breaking Point

(The New England Journal of Medicine 2023;389:100)

- *Waiting lists have surged post-pandemic.*
- *Public satisfaction plummeted to a record low of 21% (British Social Attitudes Survey 2025)*
- *Harm from NHS treatment, care or the lack of care has risen to 9.7% from 4.8% in 2001 and 2.5% in 2013 (BMJ Quality & Safety 2025)*
- *One in five doctors wants to quit UK (GMC Survey 2025)*

"We cannot solve our problems with the same thinking we used when we created them."

Albert Einstein, 1879 - 1955



"Jade can be polished with the rocks from another mountain."

Classic of Poetry, c. 800-900 BCE



- **King's CICM is aligned with**
 - WHO Traditional Medicine Strategy 2025-2034,
 - NHS Priorities, and
 - King's Strategic Vision 2029 / Strategy 2030.
- **King's CICM will build upon *well-established***
 - international standards,
 - good practice guidelines and
 - collaboration networks, which will also support the integration of other ethnic wisdom, e.g., Indian traditional medicines, into tomorrow's medicine and healthcare.

Our Ambition:

To establish King's CICM as a platform that:

- Engages KHP staff in integrative Chinese medicine (ICM) innovation.
- Attracts philanthropic funding for impactful projects.
- Supports collaborations with global partners.

Building on Excellence

- Leverages King's world-leading health sciences and legacy in TCM and natural product research.
- Draws inspiration from the EU's FP7 GP-TCM Project and its international network.



King's CICM will build upon our world-leading health sciences

King's College London in World University Rankings (QS 2026*):

- **No. 1** in Nursing
- **No. 4** in Dentistry
- **No. 11** in Life Sciences and Medicine

* QS: Quacquarelli Symonds, the name of the British company that publishes the rankings.



King's College London




St Thomas' Hospital



Maudsley Hospital



King's College Hospital



Guy's Hospital

KING'S HEALTH PARTNERS

Pioneering better health for all

Prof Graham Lord's pioneering studies on aristolochic acid nephropathy and carcinogenesis have made botanical use *safer*

- Impactful publications *in Lancet, BMJ, AJKD, AIM, etc.*



- **Lord GM**, et al. *Lancet*. 1999;354:481-2
Nephropathy caused by Chinese herbs in the UK
- **Lord GM**, et al. *Lancet*. 2001;358:1515-6
Urothelial malignant disease and Chinese herbal nephropathy
- **Lord GM**, et al. *Am J Kidney Dis*. 2004;43:e11-7
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy
- Cronin AJ, ..., **Lord GM**. *Nephrol Dial Transplant*. 2002;17:524-5
Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy
- Gökmen MR, **Lord GM**. *BMJ*. 2012;344:e4000.
Aristolochic acid nephropathy
- Gökmen MR, ..., **Lord GM**. *Ann Intern Med*. 2013;158:469-77.
The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review

Prof Graham Lord
KCL Senior Vice President
KHP Executive Director

Dr Qihe Xu: Integrating efficacy & safety, good practices, collaboration

- Impactful publications *in Science, Phytomedicine, J Ethnopharmacol, etc.*
 - **Xu Q**, et al. The hunt for anti-fibrotic and pro-fibrotic botanicals. *Science* 2014;346 (6216 Suppl):S19-20.
 - Williamson EM, Chan K, **Xu Q** et al. Evaluating the safety of herbal medicines: Integrated toxicological approaches. *Science* 2015, 347(6219 Suppl), S21-3.
 - Hu Q, ... **Xu Q**. *In vitro* anti-fibrotic activities of herbal compounds and herbs. *Nephrol Dial Transplant* 2009;24:3033-41.
 - Bunel V, Qu F, Duez P, ... **Xu Q**. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. *World Journal of Traditional Chinese Medicine* 2015;1:47-66.
 - Holden F, Amin V, Kuek D, ... **Xu Q**. Taming the fire of nephrotoxic botanicals. *World Journal of Traditional Chinese Medicine* 2019;5:151-63.
 - Zhou S, Yin X, Yuan J, ... **Xu Q**. Antifibrotic activities of Scutellariae Radix extracts and flavonoids: comparative proteomics reveals distinct and shared mechanisms. *Phytomedicine* 2022;100:154049.
 - Uzuner H, ... **Xu Q**. Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. *J Ethnopharmacol* 2012;140:458-68.
 - **Xu Q**, Bauer R, Hendry BM et al. The Quest for Modernisation of Traditional Chinese Medicine. *BMC Complement Altern Med* 2013;13:132.



Dr Qihe Xu

Director, King's CICM

Prof. Peter Hylands, Prof. Peter Houghton and Prof. Bob Hider's foundational work in pharmacognosy and medicinal chemistry



Professor Peter Hylands †

Founding Co-Director, King's CICM
Head, Institute of Pharmaceutical Science
King's College London



Professor Peter Houghton †

Emeritus Professor of Pharmacognosy
Institute of Pharmaceutical Science
King's College London



Professor Robert Hider

Emeritus Professor of Medicinal Chemistry
Institute of Pharmaceutical Science
King's College London



King's spearheaded the FP7 GP-TCM Project, creating a global network and a series of impactful publications



- From a 3.5-year project to a sustainable international platform for collaboration in developing, disseminating and implementing good practices in TCM R&D.
- Developed a GP-TCM network of 200 scientists from 24 countries and 110 institutions → GP-TCM RA, a UK-based charity, an international society, an EMA/HMPC Interested Party, which has >300 members worldwide.
- Submitted 117 reports to the European Commission proposing TCM a priority for future EU-China cooperation.
- 47 papers on good practices, priorities, challenges, opportunities and state of the art of TCM omic studies.



Dr Qihe Xu



Prof. Bruce Hendry



Prof. Peter Hylands †



Prof. Peter Houghton †

King's PIs of the FP7 GP-TCM project



Distribution of GP-TCM members within and beyond the EU.

[Uzuner H, et al. J Ethnopharmacol 2012](#)

GP-TCM RA Membership	
As of 12 December 2024	
Corporate Members	5
Institutional Members	8
Life Members	45
Honorary Members	15
Ordinary Full Members	251
Student Members	36

By courtesy of President Report by Professor Clara Lau, who co-chairs the King's CICM Honorary Advisory Board





“Modern medicine can learn from traditional practices.”


The FP7 GP-TCM Project concluded

The screenshot shows the CORDIS website interface. At the top, there is the European Commission logo and navigation options like 'Log in' and 'English'. The main header reads 'CORDIS - EU research results' with a '30' anniversary logo for 2024. Below this is a breadcrumb trail: 'Home > Thematic Packs > Projects & Results > Videos & Podcasts > News > Datalab > Search'. A yellow banner indicates 'Content archived on 2024-06-18'. The project title 'Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era' is prominently displayed, along with a 'Results in Brief' tab. A red box highlights the headline 'Modern medicine can learn from traditional practices'. Below this, a short summary states: 'Researchers have finalised a picture of current traditional Chinese medicine (TCM) research practices in the EU and on the use, safety and efficacy of this ancient medical system.' There is a 'HEALTH' tag and an image of traditional Chinese medicine ingredients. To the right, a 'Project Information' sidebar provides details: 'GP-TCM', Grant agreement ID: 223154, 'Project closed', Start date: 1 May 2009, End date: 31 October 2012, 'Funded under' Specific Programme "Cooperation": Health, 'Total cost' € 1 117 778,00, 'EU contribution' € 995 100,00, and 'Coordinated by' KING'S COLLEGE LONDON, United Kingdom.

Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities.

Uzuner H, et al. *J Ethnopharmacol.* 2012;140:458-68.

GP-TCM RA regards integration a central strategy for innovation and emphasizes integrity and GxP



The quest for modernisation of traditional Chinese medicine.
Xu Q, et al. *BMC Complement Altern Med* 2013;13:132
(234 citations)



Integrative Chinese medicine (ICM)

- A framework to catalyse medical innovation, blending TCM wisdom with modern science (*Xu & Hylands, 2017*).
- Applied in nephrology to study kidney defence mechanisms and metabolic regulation in acute and chronic kidney disease.
 - Xu Q, Hylands PJ. Integrative Chinese Medicine. *GP-TCM RA Newsletter*, 2017
 - Xu Q. Professor Peter Hylands' contributions to integrative Chinese medicine. *GP-TCM RA Newsletter*, Oct. 2019.
 - Xu Q. Let traditional wisdom inspire: a nephrologist's view. *GP-TCM RA Newsletter*, Aug. 2019

The March 2017 Newsletter of The GP-TCM Research Association

Editorial

Integrative Chinese Medicine

Dr Qihe Xu, Editor-in-chief & BoD Member, GP-TCM RA; Co-Director, Centre for Integrative Chinese Medicine, King's College London. qihe.xu@kcl.ac.uk

Professor Peter Hylands, Treasurer & BoD Member, GP-TCM RA; Head of Institute of Pharmaceutical Science and Co-Director, Centre for Integrative Chinese Medicine, King's College London. peter.2.hylands@kcl.ac.uk

According to Professor Tu (*Nat Med* 2011;17:1217-1220), her groundbreaking discovery of artemisinin was inspired by the works by Ge Hong (283-343), who is also widely acknowledged as the earliest to describe faecal transplantation as a useful therapy (*Nature* 2016;540:S110). It was not until very recently that FDA came to appreciate the importance of faecal transplantation and that scientists came to understand the underlying mechanisms, involving gut flora. Ge Hong was also the earliest to document the health benefits of intermittent fasting, which is now understood to have health benefits by inducing autophagy, reprogramming pancreatic cells to restore insulin generation in islets, and reducing risk factors for aging and age-related disorders (*Nature* 2009;457:726-730; *Cell* 2017;168:775-788; *Sci Transl Med* 2017;9:eaah8700).

In early February, Academician Professors Zhu Chen and Saijuan Chen published a *Cell* Leading-Edge Stories article on their journey of TCM-inspired discovery of arsenic trioxide as a new cure for leukaemia (*Cell* 2017;168:556-560). Entitled *Poisoning the Devil*, the article concluded: "Looking back to our scientific career, we have benefited a lot from the integration of western and eastern wisdoms." Integration of western and eastern wisdoms is exactly the approach that GP-TCM RA should adopt for the future.

This is particularly timely as the **Development Plan of the Belt and Road for TCM (2016-2020)** has just been jointly issued by China's State Administration of TCM and the National Development and Reform Commission. According to the Plan, China will build 30 centres for TCM around the world, formulating 20 international standards of TCM, registering 100 kinds of TCM products and setting up 50 exchange and cooperation bases of TCM by 2020. Five cooperation priorities have been proposed: policy coordination, resource sharing, people-to-people bonds, technology connectivity and unimpeded trade. Particularly relevant to the GP-TCM RA, it proposed to:

- Collaborate with renowned universities along the route to bring TCM into the higher education of these countries, expand diploma and postgraduate education and enhance quality of teaching. In countries that are ready, open more TCM-featured Confucius Institute.
- Support TCM research organisations and higher education institutions to establish joint laboratories and research centres in countries along the route, to apply internationally advanced modern scientific technologies and methodologies to large-scale scientific collaborations in research of TCM fundamental theories, TCM clinical practice and TCM products, etc. Focusing on common, prevalent and major diseases in countries along the route, carry out evidence-based research, so as to support and guide TCM products to gain entrance to the mainstream market of these countries.

"The Plan" entitled in Chinese 《中医药“一带一路”发展规划 (2016-2020年)》 can be found here: <http://mp.weixin.qq.com/s?biz=MzA5NzozNDkxOQ==&mid=2649649922&idx=2&sn=d08b00736be264b26be39485b04ed08chksm>

A few weeks ago, China's State Council published a **medium- and long-term plan to prevent and treat chronic diseases (2017-2025)**. The plan aims to improve people's health, lower the onset risks

The October 2019 Newsletter of The GP-TCM Research Association

Editorials

Professor Peter Hylands' contributions to Integrative Chinese medicine
—A tribute to our Founding Treasurer at his Memorial Service in London, 9th Oct. 2019¹



Dr Qihe Xu, Editor-in-chief & BoD Member, The GP-TCM RA; Senior Lecturer in Renal Medicine and Pharmacology Director, King's Centre for Integrative Chinese Medicine Chairman, Steering Committee, The FP7 GP-TCM Consortium (2009-2012) King's College London. E-mail: qihe.xu@kcl.ac.uk



Dear Debbie & family,
Dear Principal,
Dear colleagues & friends,
It's no secret that Peter loved China. He first lectured in China when I was still in medical school. And he had been there numerous times ever since.
As a pharmaceutical scientist, of course, he understood the huge value of Chinese Medicine as a source for drug development.
Passionate about international collaboration, Peter knew that Chinese Medicine is an integral part of mainstream medicine in China. If we wish to develop a truly engaged partnership with China in the field of health sciences, Chinese Medicine ought to be an important player!
Hence, it's completely natural that Peter had championed the King's Centre for Integrative Chinese Medicine initiative, which aims to integrate wisdoms from the West and the East to catalyse innovation and to promote collaboration.
It was Peter who first coined the name "King's Centre for Integrative Chinese Medicine". The name indicates that Chinese Medicine will be the focus of our study and that we will do this via an integrative approach.
It was also Peter who brought the new centre to life. In 2012, upon my annual appraisal, I proposed that my long-term goal was to found a new centre at King's, dedicated to Chinese Medicine-inspired research, education and care. My appraiser Professor Bruce Hendry advised that, if we believed in its value, we should work on it ASAP! And this was agreed by Peter. Together, we worked hard to convey our messages to stakeholders, and one year later, we were invited to present our case to the decision-makers. An excellent speaker, Peter was naturally the best person to present our case. He did. And we were officially accepted a King's new initiative in May 2013!
In the following years, Peter chaired 14 follow-up meetings and led the development of a business plan. We conducted omics-guided research of Chinese Medicine, offered Chinese Medicine-related teaching, and trained the first PhD student of our new Centre. By 2016, we have won King's funding priority!
Peter had also played important roles nationally and internationally. He was a senior leader of the FP7 GP-TCM Project. Funded 1m Euro by the EU in 2009, it was the 1st ever major EU-China cooperation on Chinese Medicine and it was widely acclaimed a success. As a member of the Steering Committee and Coordination Office, Peter chaired the Scientific & Technological Advisory Committee and one of our ten work packages. Three years later, the GP-TCM Research Association was founded. It quickly grew into a UK-based charity, a reputable international society and an

¹ A report of Peter's Memorial Service is available in the "Special Features" column

Open-access archives since 2008: www.gp-tcm.org/news-list

The August 2019 Newsletter of The GP-TCM Research Association

Editorials

Let Traditional Wisdom Inspire: A Nephrologist's View



Dr Qihe Xu, Senior Lecturer in Renal Medicine Director, King's Centre for Integrative Chinese Medicine Board Member and Newsletter Editor-in-chief, GP-TCM RA Chairman, Steering Committee, The FP7 GP-TCM Consortium (2009-2012) King's College London. E-mail: qihe.xu@kcl.ac.uk

Acute kidney injury (AKI) and chronic kidney disease (CKD) are interconnected conditions. They cause end-stage kidney failure, which needs expensive and painful treatments such as dialysis and renal transplantation. The incidence of AKI is on the rise and mortality associated with AKI is high¹. Data from the USA, for instance, indicate that burden of CKD increased 53% from 2002 to 2016, outpacing any other noncommunicable diseases² and by 2030, the burden of end-stage kidney disease will once again increase 29-68%³. Indeed, CKD is predicted to become a top-5 cause of mortality by 2040 worldwide⁴.

As a nephrologist and a renal scientist for thirty years, I have been frustrated by the fact that existing strategies are failing to prevent AKI, to stop AKI transition to CKD and to prevent CKD progression to end-stage kidney disease.

"Modern medicine can learn from traditional practices", concluded the FP7 GP-TCM consortium, EU's first Coordination Action on modernisation of TCM⁵. As the PI of the project, I have been invited to contribute a TCM-inspired Special Article to *Nephron*⁶, in which I propose that innovation in nephrology can be catalysed by the wisdom from *Yellow Emperor's Inner Canon*: "When there is sufficient protective *qi* inside, pathogenic factors have no way to hurt the body; when pathogenic factors cause damage, the internal *qi* must be deficient". Herein, *qi* means the internal mechanisms of the body that defend against attack⁶.

I propose that deficient understanding of renal defence mechanisms is a key blind spot in modern nephrology and the collecting duct meets many criteria as a critical renal protector against injury: it's ideally located to protect the entire kidney; it has specialised defending cells, molecules and signalling; it senses and responds to danger; and it appears to be a convergence point of regulation by mediators of AKI and CKD. Hence, AKI/CKD must be considered in light of not only attacks to nephrons, but also changes of defence mechanisms in the collecting duct⁷. To protect endogenous defence and to normalise repressed defence can then be developed as novel strategies for prevention and treatment of AKI/CKD, as the Nobel-Prize winning cancer immunotherapies do⁸.

Nephron is the original journal of nephrology that has been published continuously ever since 1964 and was the original official journal of the International Society of Nephrology⁹. An invited TCM-inspired Special Article by the journal indicates that, if properly communicated, a TCM-inspired innovation can be welcomed internationally and this, in turn, may make a special contribution in forging tomorrow's medicine.

After publishing my hypothesis as a poster at the UK Kidney Week (UKKW) 2018, the hypothesis was chosen as the theme of a stand-alone 60-minute session at the UKKW June 2019 in Brighton. Commenting on my talk, Mrs Elaine Davies, Research Director of Kidney Research UK, tweeted: "Interesting thought, 'provoking talk', followed by Dr Mark Dockrell, a renal scientist: "Real lateral thinking and a unique approach to a common problem".



Qihe first published his hypothesis as a poster at UKKW2018

www.gp-tcm.org/news-list/

The August 2019 Newsletter of The GP-TCM Research Association

Dr Mark Dockrell: "Real lateral thinking and a unique approach to a common problem!"

Kidney Research UK Director: "Interesting thought provoking talk!"

The Xu's hypothesis was well received at the UKKW2019 in Brighton

"A hypothesis is only as good as the experiments you can design to test it," advised Prof. Sir Robert Leckie, Senior President of King's College London and President of the Academy of Medical Sciences. I have designed a series of exciting proof-of-concept and translational studies and devised novel tools to enable these experiments¹. I cordially invite talented students and fellows to join me at King's College London in an epic effort to develop novel diagnosis measures on the defining capacity of the kidney and novel, TCM-inspired, science-based means to "tonify" the kidney so as to prevent and treat AKI and CKD.

What are the implications of my hypothesis to future R&D of TCM and Chinese materia medica? Despite differences between the function-oriented concept of "kidney" in TCM and the anatomical kidney, many functions of the TCM "kidney" have been scientifically proven as functions of the anatomical kidney: regulating water homeostasis, governing the bone through modulating vitamin D activation, controlling hematopoiesis through producing erythropoietin and serving as "the fountain of youth" by producing the anti-ageing hormone Klotho. What are the impacts of "kidney"-tonifying TCM drugs on functions of the anatomical kidney? Can some "kidney"-tonifying TCM drugs boost defence of the anatomical kidney and thus play important roles in AKI/CKD prevention and treatment?

To the wider biomedical and pharmaceutical community, what are the implications of the hypothesis? Given that non-immune defence mechanisms are generally overlooked in modern medicine, it is hoped that this Special Article will inspire not only nephrologists, but also other physicians and medical scientists alike, to perceive health and disease in light of the balance and imbalance between attack and defence,² as I concluded in the *Nephron* article.

The *Nephron* Special Article and this editorial are dedicated to the late Prof. Peter Hylands, co-founder of King's Centre for Integrative Chinese Medicine and the founding Treasurer of GP-TCM RA, for his irreplaceable mentorship, invaluable collaboration and inspirational encouragement and support³. I had talked with Peter for a number of times on this hypothesis and he had always been highly supportive of publishing it to enhance awareness, arouse interest and build collaboration. A Memorial in celebration of his great academic and non-academic contributions will be held at King's College London on 9th October. Should you wish to attend, please do let me know. Finally, to read the *Nephron* paper, please visit: <https://www.karger.com/Article/FullText/502452>


References:

1. Mehta RL, et al. *Lancet* 2015;385:2616-2643
2. Bowe B, et al. *JAMA Netw Open*. 2018;1: e184412
3. McCullough KP et al. *J Am Soc Nephrol* 2019;30:127-135
4. Foreman KJ, et al. *Lancet* 2018;392:2052-2090
5. <https://cordis.europa.eu/project/rcn/90960/brief/en>
6. Xu Q. *Nephron* 2019, DOI: 10.1159/000502452.
7. Sanmamed MF, Chen L. *Cell* 2018;175:313-26
8. Fine LG. *Nephron Exp Nephrol* 2003;93:e1-2

www.gp-tcm.org/news-list/



Staff: KHP Experts in Nephrology, Cardiology, Cancer, Ageing, AI and RCT, etc.
Honorary Advisory Board: 52 global leaders in Acupuncture, TCM, RCT, Pharmacology, etc.
Collaborators: NHS, WHO, industry partners, patients, and the public.



Project steering committees to conduct quality control

Holistic, personalised, function-oriented diagnoses

Four diagnostic methods (Inspection, Auscultation & olfaction, Inquiry and Palpation) are the key to TCM diagnosis

Use of herbal drugs and other types of medication

Over **11,000** botanical species, **1600** zoological species and **80** mineral substances

A traditional medicine with over 2000 years of text record

By 1911, **410** volumes, **800** Chinese *materia medica* works have been published

Non-drug therapies, e.g., acupuncture, Tai-chi and tuina

A dozen non-drug therapies also include cupping, Gua Sha, lotus position, medical Qigong, meditation, etc.

King's College London

St Thomas' Hospital

Maudsley Hospital

King's College Hospital

Guy's Hospital



King's CICM 1.0 2013-2024

King's CICM was offered KHP fund-raising priority during 2016-2020

Achievements:

- Leadership in global TCM research networks (Prof. Peter Hylands, Dr Qihe Xu)
- Commercialisation of a **21st-century TCM database** and filed an **herbal QC patent** (Prof. Peter Hylands)
- **Qihuang International Prize (2020)**, China Association of Chinese Medicine (Dr Qihe Xu, for his international contribution to TCM)
- 25 high-quality TCM related publications (Dr Qihe Xu, 3 with >200 citations).
- Organised **3 UK Kidney Week ICM or TCM related sessions** (Dr Qihe Xu)

Challenges:

- **Fundraising was paused during the COVID-19 pandemic** and did not resume until 2024, a few months after the WHO declared an end to the public health emergency of international concern for COVID-19.
- Loss of key figures (**Prof. Hylands, Prof. Houghton**).

2013

2015

2017

2019

2021

2023

2014

2016

2018

2020

2022

2024

King's CICM was approved as a KHP initiative by the KHP Research Committee in 2013

Prof. Peter Hylands passed away

King's CICM fund-raising was put on ice due to the COVID-19 pandemic, etc.

Prof. Peter Houghton passed away




King's CICM 2.0: An Updated Plan

Fundraising Goals:

- **Stage 1 (2025):** £0.5M King's CICM Empowerment Fund
- **Stage 2 (2029):** £5M King's CICM Breakthrough Fund.

Milestones: Shown below



On 8/10/2024, King's CICM fundraising was re-launched

01/01/2025 - 15/08/2025


- A renowned scientific advisory board (52 members) is established
- **King's CICM fundraising strategy & handbook are updated**
- A £1k donation: 1st HAB Meeting and Forum held
- **A £3k donation: a King's CICM website is being developed**
- A 20+ member King's CICM Faculty is established
- **A £3k donation raised for Hylands/Houghton/Ma/Mei Awards**
- King's CICM website (<https://www.kingscicm.org>) launched
- **Co-Directors and Assistant Director appointed**
- JustGiving Campaign launched for Peter Houghton Award

King's CICM official launch

- As soon as fundraising targets are met;
- **Coordinated in celebration of King's 200th anniversary**

A prestigious Honorary Advisory Board

- Chaired by Prof. YC Cheng and Prof C Clara
- Comprising 55 international leaders, offering complementary expertise in TCM, Acupuncture, Herbal Medicine, Clinical Trial, Pharmaceutical Science, etc.



Chair

Prof. Yung-Chi Cheng, Yale, USA



Co-Chair

Prof Clara Lau, HKU, Hong Kong

Leadership, Enabling and Coordination



Dr Qihe Xu

Director


Overall leadership; Kidney Research



Prof Yanzhong Wang

Co-Director

RCT, Big Data, AI, Stroke



Dr Min Zhang

Assistant Director

Cardiovascular Science & Translational Research

The King CICM Team

- **A Growing List of Principal Investigators:**

- **Nephrology:** Dr Qihe Xu, Prof Luigi Gnudi, Prof Iain Macdougall, Mr Mazhar Noor
- **Cardiovascular Biology & Neuroscience:** Dr Min Zhang, Dr Haotian Gu, Dr Richard Siow, Dr. Qiuping Zhang, Dr Po Wah So
- **Cancer and Pharmacology:** Prof. Khuloud Al-Jamal, Prof. Miraz Rahman, Prof. Eric So
- **Medical Humanities** (Prof. Fay Bound Alberti, Prof. Chris Berry)

- **A Central Enabling and Supporting Team:**

- **RCT:** Prof Yanzhong Wang, Dr Haotian Gu, Prof Iain Macdougall
- **AI & Big Data Analysis:** Prof Yanzhong Wang, Dr Haotian Gu, Dr Yunpeng Li, Dr Zhiqiang Huo
- **TCM and acupuncture:** Ms Titta M. Laattala
- **Fundraising:** Mr Alex Page and Mr Oliver Mangham
- **PPI:** Ms Deborah Johnston
- **Equality, Diversity & Inclusion (EDI), Bioimaging, and Phenomics:** Dr Po-Wah So

- **Our research priorities:** Kidney disease, heart disease, stroke, cancer, RCT, AI and TCM-inspired biomedical innovation
- As our expertise grows, our R&D remit will expand to include more health threats **aligned with patient & public needs and WHO & NHS priorities**



Executive Board
156th session

Agenda item 7

EB156(20)

10 February 2025

2. REQUESTS the Director General: **(by the WHO Executive Board)**

(1) to advance **kidney disease** as a noncommunicable disease of increasing global priority, in addition to **cancer, cardiovascular diseases (heart disease and stroke), diabetes and respiratory diseases**, as well as **mental health**, which have been recognized as the major causes of death and disability;

[https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_\(20\)-en.pdf](https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_(20)-en.pdf)

CONCLUSION: King's College London is globally renowned for excellence in conventional medicine and health sciences. Now, we are pioneering a **research-focused Integrative Chinese Medicine Platform**. The mission is bold, yet its potential is boundless—and we are inspired by the journey ahead.

If you're inspired by our vision and want to:

- **Support** our groundbreaking work
- **Collaborate** or develop institutional partnerships
- **Work or study** with our team

We'd love to hear from you...

 Email: info@kingscicm.org

 Phone: [+44 20 7848 5108](tel:+442078485108)



Acknowledgements

☐ Funders



PuraPharm PhD Scholarship, Sino-British Fellowship Trust, Bogue Fellowship, International Society of Nephrology, The UK Centre of Chinese Medicine, and our incredibly generous philanthropist donors: Mr. A Chan, Mr. Z He, Dr. L Zhao, Dr. D Jiang

☐ Co-workers

- **55 Members of the Honorary Advisory Board** (Co-chaired by Prof. YC Cheng, Yale, and Prof C Clara, HKU)
- **A growing list of King's CICM Faculty Members:** Dr. Q Xu (Director), Prof. Y Wang (Co-Director), Dr. M Zhang (Assistant Director), Professors FB Alberti, K Al-Jamal, C Berry, L Gnudi, IC Macdougall, KM Rahman, ECW So, and Drs H Gu, Z Huo, Y Li, R Siow, P-W So, Q Zhang, Mr. M Noor and Ms. TM Laattala.
- **A growing list of internal and external collaborators:** Prof K Brown (KCL), Mr. G He (CCMUK), JB Kopp (NIH), MSJ Simmonds (Kew), ZZ Zhao (HKBU), L Fu (CACMS), C Peng (CDUTCM), Q Wu, WB Liu (BUCM), PD Wilson (UCL), F. Tam (Imperial), D Fraser (Cardiff), ...
- **Special thanks go to the KHP Fundraising team**, especially Mr. O Mangham and Mr. A Page.